There’s a federal panel that assigns letter grades to medical tests, and the grade your test received determines two things: whether your doctor brings it up, and whether you pay for it.

Almost nobody knows this list exists. It’s public, it’s free, and it’s the closest thing to an answer key for the next twenty years of your medical care.

The U.S. Preventive Services Task Force is an independent volunteer panel of primary care and prevention experts. It reviews evidence on preventive services - screenings, counseling, preventive medications - and assigns each one a letter grade for a specific population.

The grades are not a ranking of how important a test is. They’re a statement about how confident the evidence is that the benefit outweighs the harm. That distinction matters more than it sounds, and I’ll come back to it.

A - Recommends the service. High certainty the net benefit is substantial. Offer or provide this service.

B - Recommends the service. High certainty of moderate net benefit, or moderate certainty of moderate-to-substantial net benefit. Offer or provide this service.

C - Recommends selectively offering the service based on professional judgment and patient preferences. At least moderate certainty the net benefit is small.

D - Recommends against the service. Moderate or high certainty of no net benefit, or that harms outweigh benefits.

I - Evidence is insufficient. The balance of benefits and harms cannot be determined.

Here’s why this is a money story as much as a health story.

Under the Affordable Care Act, non-grandfathered health plans are required to cover preventive services rated A or B by the Task Force without cost sharing. No copay, no coinsurance, no deductible.

Not C. Not D. Not I.

So the letter grade isn’t an academic distinction - it’s the line between a test that costs you nothing and a test you may well be billed for. If a clinician suggests something and you want to know why it’s free, or why it isn’t, this list is the answer.

Current recommendations relevant to this age band, with the populations they apply to:

Hypertension screening - adults 18 and older - Grade A

Colorectal cancer screening - adults 50 to 75 - Grade A

Colorectal cancer screening - adults 45 to 49 - Grade B

Cervical cancer screening - women 21 to 65 - Grade A

Tobacco cessation interventions - nonpregnant adults who use tobacco - Grade A

Breast cancer screening, biennial mammography - women 40 to 74 - Grade B

Lung cancer screening, annual low-dose CT - adults 50 to 80 with a 20 pack-year history who currently smoke or quit within the past 15 years - Grade B

Prediabetes and type 2 diabetes screening - adults 35 to 70 with overweight or obesity - Grade B

Statin for primary cardiovascular prevention - adults 40 to 75 with one or more CVD risk factors and a 10-year risk of 10% or greater - Grade B

Hepatitis C screening - adults 18 to 79 - Grade B

Depression screening - adults - Grade B

Anxiety disorder screening - adults 64 or younger - Grade B

Unhealthy alcohol use screening - adults 18 and older - Grade B

Osteoporosis screening - postmenopausal women under 65 at increased risk - Grade B

A few of these are worth pausing on.

Colorectal screening starts at 45, not 50. That moved in 2021. If your mental model was set when you were younger, you are potentially five years behind. It’s a B from 45 to 49 and an A from 50 to 75 - meaning the evidence gets stronger, not that the earlier screening is optional.

Hepatitis C is a one-time screen for essentially every adult, 18 to 79. Most people in this cohort have never been offered it and assume it’s for someone else. It’s a B for the whole age range.

Anxiety screening carries an explicit age ceiling of 64. Not because anxiety stops at 65, but because the Task Force found the evidence insufficient above that age. That’s what a grade boundary usually means - a gap in the evidence, not a gap in the condition.

Prostate cancer screening is the example worth understanding, because it’s where the grading system does something more useful than a yes or no.

For men 55 to 69, the Task Force concluded the benefits and harms of PSA-based screening are closely balanced, and that the decision should be an individual one made after a conversation about tradeoffs. For men 70 and older, it recommends against screening - the benefits don’t outweigh the harms.

That first one is a C, and a C is not a shrug. It’s a specific claim: we looked hard, the net benefit is real but small, and at that size your values legitimately change the answer. Someone who would want aggressive treatment for a slow-growing cancer and someone who wouldn’t should rationally make different choices, and the evidence can’t adjudicate between them.

Most medical guidance pretends this category doesn’t exist. It does, and knowing when you’re in it is the difference between an informed decision and a defaulted one.

A D grade means the Task Force reviewed the evidence and concluded a test does more harm than good in asymptomatic people. An I means nobody knows yet.

Plenty of things marketed directly to people our age - full-body scans, broad supplement panels, various “executive physical” packages - sit in D or I territory, or have never been evaluated at all. That doesn’t automatically make them worthless. It does mean that if someone is selling one to you, the evidence base is not what’s driving the pitch.

None of this replaces a clinician who knows your history. Family history, existing conditions, and risk factors all move these lines, and the Task Force recommendations are written for the general asymptomatic population - which may or may not be you.

But you should know the list exists. It’s the rare case where the government has already done the hard synthesis, published it for free, and tied your insurance coverage to the result.

This is not medical advice and I’m not a physician. Recommendations change - the breast cancer guidance was updated in 2024, osteoporosis in 2025. Check the current statement before acting, and talk to a clinician who knows your history.

Grade Definitions - U.S. Preventive Services Task Force

A and B Recommendations - USPSTF

Prostate Cancer: Screening - USPSTF

Colorectal Cancer: Screening - USPSTF

Preventive care benefits for adults - HealthCare.gov